Maine Lawmakers Challenge ModivCare’s $750 Million Contract Amid Bankruptcy Crisis

State legislators in Maine are intensifying scrutiny over healthcare services provider ModivCare Inc., questioning how a bankrupt company can responsibly manage a substantial $750 million patient transportation agreement. The controversy emerges just weeks after the firm’s Chapter 11 filing in August, creating significant uncertainty around both the contract and the company’s future.

Financial Freefall and Regulatory Scrutiny

ModivCare’s stock has collapsed to penny stock status, currently trading around $0.44 on the over-the-counter market under the ticker symbol MODVQ following its delisting from Nasdaq. This dramatic decline coincides with CEO Heath Sampson’s appearance before Maine’s health committee on September 9, where he faced tough questioning about the company’s ability to fulfill its contractual obligations while carrying over $1.1 billion in debt.

Despite Sampson’s assurances that bankruptcy proceedings wouldn’t affect service delivery and would ultimately strengthen the company, lawmakers remain deeply skeptical. Their primary concern centers on whether an insolvent organization can reliably execute a decade-long, three-quarter-billion-dollar contract for critical patient transportation services.

Restructuring Efforts and Financial Challenges

The company is pursuing an aggressive restructuring plan that aims to reduce its staggering $1.1 billion debt burden by approximately 85%. This effort has gained support from more than 90% of senior creditors, who have additionally committed $100 million in emergency financing to sustain operations during the bankruptcy process.

However, ModivCare’s financial transparency has raised additional concerns. The company failed to meet its Q2 2025 financial reporting deadline, citing an ongoing internal investigation and a substantial goodwill impairment charge of at least $250 million. Preliminary indications suggest both revenue and EBITDA performance will show significant deterioration when finally reported.

Should investors sell immediately? Or is it worth buying ModivCare?

Contract Uncertainty and Legal Challenges

The massive Maine transportation agreement now hangs in the balance as ModivCare navigates its financial crisis. Implementation has been temporarily suspended after two local transportation companies filed legal challenges against the contract award process.

Sampson has attributed the company’s debt problems to expensive acquisitions predating his leadership tenure, emphasizing that the debt restructuring will create a more sustainable financial foundation. Nevertheless, the fundamental question remains unanswered: how can a bankrupt entity realistically manage a long-term contract of this magnitude?

Analyst Coverage Evaporates

The investment research community has largely abandoned coverage following ModivCare’s stock exchange delisting and transition to OTC trading. Previous analyst recommendations, which included price targets ranging from $8.38 to $14.70 per share, now appear completely disconnected from current reality.

All eyes are now focused on September 19, when ModivCare management has scheduled a conference to provide updates on restructuring progress. Until then, the company’s shares remain highly speculative, Maine officials await satisfactory answers, and the future of both the contract and the company remains uncertain.